DE10248141B4 - Nukleinsäuren und deren Verwendung für die Gentherapie - Google Patents

Nukleinsäuren und deren Verwendung für die Gentherapie Download PDF

Info

Publication number
DE10248141B4
DE10248141B4 DE10248141A DE10248141A DE10248141B4 DE 10248141 B4 DE10248141 B4 DE 10248141B4 DE 10248141 A DE10248141 A DE 10248141A DE 10248141 A DE10248141 A DE 10248141A DE 10248141 B4 DE10248141 B4 DE 10248141B4
Authority
DE
Germany
Prior art keywords
vector
sequence
tumor
vectors
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE10248141A
Other languages
German (de)
English (en)
Other versions
DE10248141A1 (de
Inventor
Reinhard WÄHLER
Frank Schnieders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provecs Medical De GmbH
Original Assignee
University Medical Center Hamburg-Eppendorf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE10248141A priority Critical patent/DE10248141B4/de
Application filed by University Medical Center Hamburg-Eppendorf filed Critical University Medical Center Hamburg-Eppendorf
Priority to AU2003273983A priority patent/AU2003273983A1/en
Priority to JP2004544141A priority patent/JP4615311B2/ja
Priority to PCT/EP2003/011252 priority patent/WO2004035799A2/de
Priority to EP03757951.3A priority patent/EP1556411B1/de
Priority to PT37579513T priority patent/PT1556411E/pt
Priority to ES03757951.3T priority patent/ES2440951T3/es
Priority to SI200332329T priority patent/SI1556411T1/sl
Priority to US10/530,706 priority patent/US8067227B2/en
Priority to DK03757951.3T priority patent/DK1556411T3/da
Publication of DE10248141A1 publication Critical patent/DE10248141A1/de
Application granted granted Critical
Publication of DE10248141B4 publication Critical patent/DE10248141B4/de
Priority to JP2010192832A priority patent/JP2011036251A/ja
Priority to CY20131101171T priority patent/CY1114777T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE10248141A 2002-10-11 2002-10-11 Nukleinsäuren und deren Verwendung für die Gentherapie Expired - Fee Related DE10248141B4 (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DE10248141A DE10248141B4 (de) 2002-10-11 2002-10-11 Nukleinsäuren und deren Verwendung für die Gentherapie
US10/530,706 US8067227B2 (en) 2002-10-11 2003-10-10 Viral vectors and the use of the same for gene therapy
PCT/EP2003/011252 WO2004035799A2 (de) 2002-10-11 2003-10-10 Virale vektoren und deren verwendung für die gentherapie
EP03757951.3A EP1556411B1 (de) 2002-10-11 2003-10-10 Adenovirale Vektoren die Einzelketten Interleukin-12 und 4-1BB Ligand exprimieren
PT37579513T PT1556411E (pt) 2002-10-11 2003-10-10 Vetores adenovirais que expressam interleucina-12 de cadeia única e ligando 4-1bb
ES03757951.3T ES2440951T3 (es) 2002-10-11 2003-10-10 Vectores adenovirales que expresan la interleucina-12 de cadena sencilla y el ligando 4-1BB
AU2003273983A AU2003273983A1 (en) 2002-10-11 2003-10-10 Viral vectors and the use of the same for gene therapy
JP2004544141A JP4615311B2 (ja) 2002-10-11 2003-10-10 ウイルスベクターおよびその遺伝子治療のための使用
DK03757951.3T DK1556411T3 (da) 2002-10-11 2003-10-10 Adenovirusvektorer som udtrykker enkeltkædet interleukin-12 og 4-1BB ligand
SI200332329T SI1556411T1 (sl) 2002-10-11 2003-10-10 Adenovirusni vektorji, ki eksprimirajo enojnoveriĹľni interlevkin-12 in 4-1BB ligand
JP2010192832A JP2011036251A (ja) 2002-10-11 2010-08-30 ウイルスベクターおよびその遺伝子治療のための使用
CY20131101171T CY1114777T1 (el) 2002-10-11 2013-12-27 Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10248141A DE10248141B4 (de) 2002-10-11 2002-10-11 Nukleinsäuren und deren Verwendung für die Gentherapie

Publications (2)

Publication Number Publication Date
DE10248141A1 DE10248141A1 (de) 2004-09-02
DE10248141B4 true DE10248141B4 (de) 2007-04-19

Family

ID=32102775

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10248141A Expired - Fee Related DE10248141B4 (de) 2002-10-11 2002-10-11 Nukleinsäuren und deren Verwendung für die Gentherapie

Country Status (11)

Country Link
US (1) US8067227B2 (enExample)
EP (1) EP1556411B1 (enExample)
JP (2) JP4615311B2 (enExample)
AU (1) AU2003273983A1 (enExample)
CY (1) CY1114777T1 (enExample)
DE (1) DE10248141B4 (enExample)
DK (1) DK1556411T3 (enExample)
ES (1) ES2440951T3 (enExample)
PT (1) PT1556411E (enExample)
SI (1) SI1556411T1 (enExample)
WO (1) WO2004035799A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069272A2 (en) * 2003-02-05 2004-08-19 Movecare Ltd Adjuvant combination for use in the immunization of a mamal comprising il2 and il12
DE102005055128B4 (de) * 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
PL3351261T3 (pl) 2011-10-11 2021-12-06 Universität Zürich Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
SG10201913163PA (en) 2015-12-18 2020-03-30 Oncosec Medical Inc Plasmid constructs for heterologous protein expression and methods of use
EP3211000B1 (en) * 2016-02-25 2019-01-30 Provecs Medical GmbH Novel immunostimulating vector system
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
KR20240144261A (ko) 2017-02-28 2024-10-02 사노피 치료적 rna
EP3628010A4 (en) 2017-05-02 2021-02-17 Nektar Therapeutics IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE
AU2019208892B2 (en) * 2018-01-19 2022-02-03 Kolon Life Science, Inc. Recombinant vaccinia virus and pharmaceutical composition comprising same
KR102907902B1 (ko) 2018-08-01 2026-01-02 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
US11230699B2 (en) * 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020018767A1 (en) * 2000-07-27 2002-02-14 See-Woo Lee Anti-cancer cellular vaccine
WO2002027007A2 (en) * 2000-09-25 2002-04-04 Regents Of The University Of Michigan Production of viral vectors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
WO2000041508A2 (en) 1999-01-15 2000-07-20 Mount Sinai School Of Medicine Of The City University Of New York Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020018767A1 (en) * 2000-07-27 2002-02-14 See-Woo Lee Anti-cancer cellular vaccine
WO2002027007A2 (en) * 2000-09-25 2002-04-04 Regents Of The University Of Michigan Production of viral vectors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MELERO i: et al. II-12 gene therapy for cancer: in synergy with other immunotherapies (2001) Trends in immunology Vol. 22(3), Seite 113-115 *
PubMed PMID 12202906 (Abstr. zu: Gillies, S.D. et al., Cancer Immunol. Immunother. 51(8), 2002, S. 449-60 *
Tan J.T. et al., J. Immunol. 163, 1999, S. 4859-68 *

Also Published As

Publication number Publication date
CY1114777T1 (el) 2016-12-14
EP1556411A2 (de) 2005-07-27
AU2003273983A1 (en) 2004-05-04
DE10248141A1 (de) 2004-09-02
WO2004035799A2 (de) 2004-04-29
JP4615311B2 (ja) 2011-01-19
SI1556411T1 (sl) 2014-01-31
AU2003273983A8 (en) 2004-05-04
WO2004035799A3 (de) 2004-06-10
JP2006511212A (ja) 2006-04-06
US20060153805A1 (en) 2006-07-13
DK1556411T3 (da) 2014-01-20
JP2011036251A (ja) 2011-02-24
ES2440951T3 (es) 2014-01-31
US8067227B2 (en) 2011-11-29
PT1556411E (pt) 2014-01-07
EP1556411B1 (de) 2013-10-02

Similar Documents

Publication Publication Date Title
DE69230506T2 (de) Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
DE69637480T2 (de) Bioaktive il-12 fusionsproteine
DE69836219T2 (de) Verwendung von herpes-vektoren zur tumortherapie
DE69435096T2 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
DE69434781T2 (de) Defektive rekombinante adenoviren zur tumor-gentherapie
DE69735643T2 (de) IL12 zur Gentherapie der Tumoren
DE69834330T2 (de) Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie
DE60038503T2 (de) AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER
DE69313443T2 (de) Warte-effekt bei tumorzerstörender therapie
DE69636863T2 (de) Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
EP1556411B1 (de) Adenovirale Vektoren die Einzelketten Interleukin-12 und 4-1BB Ligand exprimieren
DE69839273T2 (de) Krebsimmuntherapie mit semi-allogenen zellen
DE69231250T2 (de) Kombinierte zelluläre und immunsuppressive therapien
DE69706593T2 (de) Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier
DE60309513T2 (de) Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten
JPH06508039A (ja) 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス
EP2658566A1 (de) Sirna gegen cbl-b und optional il2 und il12 zur verwendung in der behandlung von krebs
KR100481230B1 (ko) 이식에서 이식편 거부를 예방하고, 보편적인 유전자 치료 숙주세포를 생산하는 방법
DE3308030A1 (de) Tierische interferone
WO1995023216A1 (de) Verfahren zur herstellung von klonogenen fibroblasten, verfahren zur gentransfizierung von fibroblasten und so erhaltene gentransfizierte fibroblasten
WO1996005866A2 (de) Lebendvakzine zur behandlung von tumorerkrankungen
CN105079792A (zh) Il-17在提高间充质干细胞免疫抑制功能中的应用
DE60035049T2 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
DE69535288T2 (de) Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren
DE69534633T2 (de) Implantat und vektor zur behandlung von erworbenen krankheiten

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8125 Change of the main classification

Ipc: C12N 15/861 AFI20051017BHDE

8364 No opposition during term of opposition
R082 Change of representative

Representative=s name: KEHL, ASCHERL, LIEBHOFF & ETTMAYR PATENTANWAEL, DE

R081 Change of applicant/patentee

Owner name: PROVECS MEDICAL GMBH, DE

Free format text: FORMER OWNER: UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF (UKE), 20251 HAMBURG, DE

R082 Change of representative

Representative=s name: GRUENECKER PATENT- UND RECHTSANWAELTE PARTG MB, DE

Representative=s name: KEHL, ASCHERL, LIEBHOFF & ETTMAYR PATENTANWAEL, DE

Representative=s name: KEHL, ASCHERL, LIEBHOFF & ETTMAYR - PATENTANWA, DE

R082 Change of representative

Representative=s name: GRUENECKER PATENT- UND RECHTSANWAELTE PARTG MB, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee